Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France, gives her thoughts on how the field of renal cell carcinoma (RCC) is evolving, in particular the development of a patient-based treatment strategy, including the use of a gene expression signature to determine treatment pathways in patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).